Tissue Remodeling in Adenomyosis Pathophysiology

Overview

About this study

The aims of this study are to delineate expression of a novel REST-miRNA mediated tissue remodeling pathway in adenomyosis and define its function using novel experimental mouse models, and to delineate REST-miR-137-3p (A) and REST-miR-29b-3p (B) mediators and mechanisms relevant to adenomyosis pathophysiology.

Adenomyosis is a nonmalignant uterine disease characterized by endometrial stroma and glands found within the myometrium.1 Adenomyosis has been associated with heavy and painful menstrual periods, pelvic pain, pain with intercourse, and reproductive dysfunction. However, now that imaging is identifying adenomyosis in younger and more varied women than those electing hysterectomy where pathological diagnosis occurred, many of our assumptions about the clinical disease are changing.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria;

Pre-menopausal (21 - 50 years of age).
Study group will consist of women seeking hysterectomy for possible adenomyosis adenomyomectomy.
Controls will consist of women seeking hysterectomy for uterine prolapse or pelvic pain or transgender men prior to androgen treatment and whose pathology shows a uterus < 100 grams with no evidence of adenomyosis, endometriosis, or leiomyomas.

Exclusion Criteria:

No ua\se of GnRH analogues, aromatase inhimitors, selective E2 or P4 receptor modulators, oral contraceptives, or immunotherapy within 3 months prior to surgery in any patient.
No history /confirmation or suspicion of autoimmune disease, fibromyalgia, endometriosis, or leiomyomas in any patient.
No current or previous history of STDs, pelvic inflammatory disease, endometrial/cervical cancer in any patient.
Women who do not exhibit menstrual cycles.

Eligibility last updated 10/21/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Elizabeth Stewart, M.D.	Open for enrollment	Contact information: Maureen Lemens C.C.R.C. (507) 293-1487 Lemens.Maureen@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elizabeth Stewart, M.D.

Open for enrollment

Contact information:

Maureen Lemens C.C.R.C.

(507) 293-1487

Lemens.Maureen@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials